BiomX Inc.

BiomX Inc., trading under the ticker PHGE, is a clinical-stage biopharmaceutical company developing bacteriophage-based therapies designed to target antibiotic-resistant bacterial infections. The company entered the public markets in 2019 through its merger with Chardan NexTech Acquisition Corp, a blank-check vehicle sponsored by Chardan Capital Markets, and is listed on the NYSE American. On June 29, 2026, BiomX filed an S-1 registration statement with the SEC under accession number 0001213900-26-073197, marking continued capital markets activity in the biotechnology sector. The company's pipeline centers on precision phage therapies across indications including chronic rhinosinusitis and inflammatory bowel disease. Sign up at SpacDesk for complete filing history, SPAC transaction data, and ongoing coverage of PHGE.